Adaptimmune Therapeutics PLC
ADAPY- Exchange
- OTC
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001621227
No open-market purchases or sales by Adaptimmune Therapeutics PLC insiders were filed in the last 90 days; no institution reported holding it in 13F filings for Q2 2026; no superinvestor holds it.
Q1 2022 vs. Q4 2021
How the institutions holding Adaptimmune Therapeutics PLC changed between Q4 2021 and Q1 2022.
All holders in Q1 2022All holders in Q4 2021
| Measure | Q4 2021 | Of which not filed for Q1 2022 | Q1 2022 | Change |
|---|---|---|---|---|
| Holders | 85 | 2 | 80 | −3 |
| Shares | 113.6M | 675 | 110.1M | −3.43M (−3.0%) |
| Value | $425.9M | $3.00K | $229.2M | −$196.7M (−46.2%) |
2 institutions that held it in Q4 2021 haven't filed for Q1 2022 yet. Not filing isn't selling, so the changes leave them out.
New holders (13)
Institutions that held Adaptimmune Therapeutics PLC at the end of Q1 2022 but not at the end of Q4 2021.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Two Sigma Investments, LP | 263,960 | $544.0K | 0.00% |
| Two Sigma Advisers, LP | 105,000 | $216.0K | 0.00% |
| Acadian Asset Management LLC | 44,208 | $91.0K | 0.00% |
| Crestline Management, LP | 40,000 | $82.0K | 0.01% |
| Virtu Financial LLC | 24,470 | $50.0K | 0.00% |
| Levy Wealth Management Group, LLC | 17,590 | $36.0K | 0.01% |
| Raymond James & Associates | 10,573 | $22.0K | 0.00% |
| Running Point Capital Advisors, LLC | 10,000 | $21.0K | 0.01% |
| Quantbot Technologies LP | 2,000 | $4.00K | 0.00% |
| Aquatic Capital Management LLC | 1,600 | $3.00K | 0.00% |
| Joseph P. Lucia & Associates, LLC | 375 | $1.00K | 0.00% |
| Worth Asset Management, LLC | 600 | $1.00K | 0.00% |
| San Luis Wealth Advisors LLC | 7 | $0 | 0.00% |
Sold out (16)
Institutions that held Adaptimmune Therapeutics PLC at the end of Q4 2021 and filed for Q1 2022 without it.
| Institution | Shares, Q4 2021 | Value, Q4 2021 |
|---|---|---|
| Capital World Investors | 8,002,700 | $30.0M |
| Marshall Wace, LLP | 567,796 | $2.13M |
| Man Group plc | 135,546 | $508.0K |
| Vigilare Wealth Management | 98,450 | $369.0K |
| Henry James International Management, Inc. | 43,070 | $162.0K |
| Jane Street Group, LLC | 20,249 | $76.0K |
| XTX Topco Ltd | 17,560 | $66.0K |
| Aigen Investment Management, LP | 11,776 | $43.0K |
| Chicago Partners Investment Group LLC | 12,265 | $38.0K |
| Vectors Research Management, LLC | 7,000 | $26.0K |
| FNY Investment Advisers, LLC | 6,000 | $22.0K |
| Eagle Bay Advisors LLC | 3,388 | $15.0K |
| Heritage Wealth Advisors | 3,333 | $12.0K |
| Quadrant Capital Group LLC | 2,466 | $9.00K |
| High Net Worth Advisory Group LLC | 1,000 | $4.00K |
| Total Clarity Wealth Management, Inc. | 200 | $1.00K |
Not filed for Q1 2022 yet (2)
Institutions that held Adaptimmune Therapeutics PLC at the end of Q4 2021 and haven't filed a 13F for Q1 2022. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q4 2021 | Value, Q4 2021 |
|---|---|---|
| NEXT Financial Group, Inc | 475 | $2.00K |
| Harbour Investments, Inc. | 200 | $1.00K |